Relationship Between Weight, Efavirenz Exposure, and Virologic Suppression in HIV-Infected Patients on Rifampin-Based Tuberculosis Treatment in the AIDS Clinical Trials Group A5221 STRIDE Study | Zendy

Anne F. Luetkemeyer | Zendy; Susan L. Rosenkranz | Zendy; Darlene Lu | Zendy; Florence Marzan | Zendy; Prudence Ive | Zendy; Evelyn Hogg | Zendy; Susan Swindells | Zendy; Constance A. Benson | Zendy; Beatriz Grinsztejn | Zendy; Ian Sanne | Zendy; Diane V. Havlir | Zendy; Francesca Aweeka | Zendy

Open Access

Relationship Between Weight, Efavirenz Exposure, and Virologic Suppression in HIV-Infected Patients on Rifampin-Based Tuberculosis Treatment in the AIDS Clinical Trials Group A5221 STRIDE Study

Author(s) -

Anne F. Luetkemeyer,

Susan L. Rosenkranz,

Darlene Lu,

Florence Marzan,

Prudence Ive,

Evelyn Hogg,

Susan Swindells,

Constance A. Benson,

Beatriz Grinsztejn,

Ian Sanne,

Diane V. Havlir,

Francesca Aweeka

Publication year - 2013

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/cit246

Subject(s) - cmin , medicine , efavirenz , interquartile range , gastroenterology , pharmacokinetics , viral load , human immunodeficiency virus (hiv) , cmax , immunology , antiretroviral therapy

Rifampin (RIF) upregulates CYP 450 isoenzymes, potentially lowering efavirenz (EFV) exposure. The US EFV package insert recommends an EFV dose increase for patients on RIF weighing ≥50 kg. We conducted a pharmacokinetic study to evaluate EFV trough concentrations (Cmin) and human immunodeficiency virus (HIV) virologic suppression in patients on EFV (600 mg) and RIF-based tuberculosis treatment in the multicenter randomized trial (ACTG A5221).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research